Previous 10 | Next 10 |
Stocks rose this week, with investors piling into growth-oriented segments of the market. At the time of this recording, the S&P 500 (SP500) and Dow Industrials (DJI) were up 0.3% and 0.1% for the week, respectively. The Nasdaq (COMP) rallied by 0.9% while cryptocurrencies (and crypto sto...
Gainers: Artelo Biosciences (ARTL) +93%. ImmunoGen (IMGN) +29%. Prothena Corporation (PRTA) +26%. NantKwest (NK) +21%. Illumina (ILMN) +19%.Losers: Amicus Therapeutics (FOLD) -33%. CollPlant Biotechnologies (CLGN) -30%. Caladrius Biosciences (CLBS) -20%. Conformis (CFMS) -16%. SQZ Biotechnolo...
NantKwest, Inc. (NK) is up ~12.9% in the premarket after the company and its privately-held partner, ImmunityBio announced the FDA approval to expand the Phase I study of its T cell-based COVID-19 vaccine candidate.The cohort C expansion to the Phase 1 trial evaluating the subc...
Artelo Biosciences (ARTL) +63%.China Liberal Education Holdings Limited (CLEU) +59%.Helius Medical Technologies (HSDT) +29%.Denison Mines Corp. (DNN) +26% on $25M bought deal offering.Xeris Pharmaceuticals (XERS) +25% as EC OK's its Ogluo for severe hypoglycaemia.Inovio Pharmaceutic...
FDA authorized the expansion of the active Phase 1 COVID-19 vaccine trial and a second trial to test a novel combination of T-cell-based hAd5 subcutaneous prime vaccine with a room-temperature oral or sublingual boost, to induce comprehensive immune protection through CD4+ and CD8+ T ...
Privately-held ImmunityBio which announced to merge with NantKwest ([[NK]] -3.3%) has announced data presentation from ongoing Phase 2b study evaluating Anktiva (N-803) in non-small cell lung cancer ((NSCLC)).Clinical benefit was demonstrated in a majority of the NSCLC patients, as measured b...
Clinical benefit observed in majority of NSCLC patients who progressed on checkpoint inhibitor Anktiva ™ (also called N-803) restored or enhanced activity of checkpoint therapy even in those who progressed on the same checkpoint Activity observed regardles...
RM LAW Announces Investigation of NantKwest, Inc. PR Newswire BERWYN, Pa. , Jan. 21, 2021 /PRNewswire/ -- RM LAW, P.C. is investigating potential claims against the board of directors of NantKwest, Inc. ("NantKwest" or the "Company") (NASDAQ: NK) concerning p...
The following slide deck was published by NantKwest, Inc. in conjunction with this event. For further details see: Nantkwest (NK) Presents At 39th Annual J.P. Morgan Healthcare Conference - Slideshow
The South Africa Health Products Regulatory Authority has signed-off ImmunityBio's Phase 1 trial to evaluate its hAd5 T-cell vaccine, the company’s COVID-19 vaccine candidate.The same vaccine is currently being tested in a similar Phase 1 trial in the U.S., with no safety con...
News, Short Squeeze, Breakout and More Instantly...
Imerys Enters Long-Term Partnership with TotalEnergies for Renewable Power at its Santa Barbara County Facility PR Newswire A TotalEnergies solar and battery storage solution to bring 130-year-old Lompoc industrial site into new era of sustainability and smart energy manag...
Creates Leading Immunotherapy and Cell Therapy Company ImmunityBio , Inc. and NantKwest , Inc. ( NASDAQ: NK ), today announced the completion of their previously announced 100% stock-for-stock merger. This follows the satisfaction of all customary closing conditi...
NantKwest, Inc . ( NASDAQ: NK ), a clinical-stage, natural killer cell-based therapeutics company, today announced that its stockholders approved by the required vote each of the proposals related to the pending merger of NantKwest and ImmunityBio, Inc. presented at the special ...